| |
Number of patients (%)
|
|---|
|
Histology
| |
|
Non-small cell lung cancer
|
56 (88%)
|
|
Other
|
6 (9%)
|
|
No pathology
|
2 (3%)
|
|
Dose schedule
| |
|
6 Gy × 5 fractions
|
2 (3%)
|
|
8 Gy × 5 fractions
|
7 (11%)
|
|
9 Gy × 5 fractions
|
1 (1.5%)
|
|
10 Gy × 5 fractions
|
10 (16%)
|
|
10.5 Gy × 5 fractions
|
7 (11%)
|
|
12 Gy × 4 fractions
|
17 (27%)
|
|
18 Gy* × 3 fractions
|
19 (29%)
|
|
Other
|
1 (1.5%)
|
|
Tumor size
| |
|
≤ 3 cm
|
36 (56%)
|
|
>3 cm
|
28 (44%)
|
|
SBRT indication
| |
|
Refused surgery
|
7 (11%)
|
|
Medically inoperable
|
47 (73%)
|
|
Surgically incurable
|
10 (16%)
|
|
Location
| |
|
Central
|
23 (36%
|
|
Peripheral
|
41 (64%)
|
- Baseline characteristics and treatment details for 64 evaluable patients treated with FFF lung SBRT.
- *Includes 20 Gy in 3 fractions without heterogeneity correction.
